Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism

Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been devoted to the discovery of new potent inhibitors. Until now, fourteen EGFR small-molecule inhibitors have been globally...

Descripción completa

Detalles Bibliográficos
Autores principales: Abourehab, Mohammed A. S., Alqahtani, Alaa M., Youssif, Bahaa G. M., Gouda, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587155/
https://www.ncbi.nlm.nih.gov/pubmed/34771085
http://dx.doi.org/10.3390/molecules26216677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587155/
https://www.ncbi.nlm.nih.gov/pubmed/34771085
http://dx.doi.org/10.3390/molecules26216677

Ejemplares similares